Evidence and regulatory context for peptide-based treatments connected to hormonal / endocrine.
Established / approved options
Teriparatide and abaloparatide have product-specific endocrine and bone indications.
Being researched
CJC-1295 and ipamorelin are unapproved and not recommended for hormone optimization.
How to use this page
Established options appear before experimental compounds. Goal relevance never overrides regulatory status or evidence quality.
Next step
Open the relevant treatment review for sources, risks, contraindications, and evidence gaps.
MyPeptideQuest
Information only. Not medical advice. No dosing or self-treatment instructions are provided.